SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program

• click to rate

  Posted by Two Blokes Jul 21 - Filed in Stock - 12 views
  
  Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.